Cidara Therapeutics snags $32 mln Series A

Biopharmaceutical firm Cidara Therapeutics said Monday that it has secured $32 million in Series A funding. 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners were the lead investors. In addition to the financing, the firm has hired Dr. Jeffrey Stein as president and CEO. It has also named Dr. Kevin Judice and Dr. H. Shaw Warren as chief operating officer and chief scientific officer respectively. Warren will also join Cidara’s scientific advisory board.  And, Dr. Ken Bartizal has been added as chief development officer while Dr. Dirk Thye has joined Cidara as chief medical officer.

newspaper

peHUB First Read

Take a break this morning to find out the latest private equity news including fund closes from Adveq, Frazier Healthcare and Pitango and why biotech CEOs don’t know it all.

AmerisourceBergen Announces Sale of AndersonBrecon

AmerisourceBergen Corporation has agreed to sell its contract packaging business, AndersonBrecon to an entity formed by affiliates of an investor group led by Frazier Healthcare VI, L.P. for the purpose of acquiring AndersonBrecon. The group is paying $308 million in cash, which is subject to adjustments. AmerisourceBergen is a pharmaceutical services company that serves the United States, Canada and selected global markets.

peHUB First Read

Click on this morning’s FirstRead to find out more about Frazier Healthcare’s $400m fundraising, Google’s visual dictionary and where to get a top class take-out.

Alcresta Raises $10M Series A

Alcresta, a Newton, Mass.-based company that is developing enzyme-based nutritional products, has raised $10 million in Series A financing led by Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. PRESS RELEASE: Alcresta, a company developing innovative enzyme-based nutritional products for infants, adults and patients battling acute or chronic conditions, today announced a $10 million Series […]

Biogen Buys VC-Backed Stromedix

Publicly traded Biogen Idec is buying venture-backed Stromedix Inc. Under the terms of the deal, Biogen Idec will make an upfront cash payment of $75 million and additional payments of up to $487.5 million based on certain milestones. Stromedix’s investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and […]

Allena Pharmaceuticals Launches with $15M

Allena Pharmaceuticals Inc., a company developing oral protein therapeutics, has raised $15 million in a first round of venture funding. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the Series A round. The funding will help fund development. Allena Pharmaceuticals is based in Newton, Mass.

Frazier Healthcare, NEA Team Up to Buy Dialysis Clinics

Frazier Healthcare and New Enterprise Associates have partnered to buy 30 dialysis clinics from DaVita and DSI Renal, the firm announced Monday. The resulting company, DSI, will focus on providing care for patients with chronic kidney failure or end stage renal disease. Healthcare executives Robert Lefton and Craig Goguen will lead the new company, serving as executive chairman and chief executive. The company’s board will include Frazier general partner Nader Naini; NEA partner Mohamad Makhzoumi; NEA general partner Ryan Drant; and Frazier principal Ben Magnano. No terms of the acquisition were released.

Frazier Healthcare Adds Tadataka Yamada

Frazier Healthcare has named Tadataka Yamada as a senior executive-in-residence with the firm. Yamada will work with the firm’s growth equity and venture capital teams to pursue investments in healthcare companies in the U.S. and in emerging markets. Yamada was most recently the president of the Global Health Program for the Bill & Melinda Gates Foundation. Frazier Healthcare has $1.8 billion under management.

Frazier Completes Acquisition of CareFusion Business

Frazier Healthcare has completed its acquisition of the Onsite Services instrument management and repair business of publicly traded CareFusion. Financial terms of the deal were not released. OnSite Services delivers education-based medical instrument repair and instrument management programs to hospital systems domestically, the company said in a statement. The deal was first announced in January.

Informed Medical Merges with IC Axon

Private equity-backed Informed Medical Communications – a provider of peer-to-peer medical forums, training services and integrated medical communications for the biopharmaceutical industry – has merged with healthcare training company IC Axon. Financial terms of the deal were not released. Edison, New Jersey-based Informed Medical Communications is backed by firm Frazier Healthcare. Montreal-based IC Axon was advised by Fairmount Partners. Excel Partners advised Informed Medical.

Gilead Sciences Pays $375M For Calistoga Pharma

Publicly traded Gilead Sciences Inc. will pay $375 million to acquire venture-backed Calistoga Pharmaceuticals, a company developing treatments for cancer and inflammatory diseases. Calistoga could net up an additional $225 million in milestone-based earn-outs. Seattle-based Calistoga has raised more than $90 million from venture investors including Alta Partners, Amgen Ventures, Frazier Healthcare and Three Arch Partners and Latterell Venture Partners.

Frazier Healthcare Promotes Morfitt and Magnano

Brian Morfitt was promoted to partner of Frazier Healthcare’s growth equity team. Ben Magnano was also named a principal with Frazier’s growth equity team, according to a statement Wednesday. Frazier, with offices in Seattle and Menlo Park, Calif., provides growth equity and VC funding to healthcare companies.

VC Jobhunting: Gordie Nye Lands At Zeltiq

Nye was working out of his home office in Southern California after his East Coast firm, Prism VentureWorks in Needham, suspended efforts to raise its sixth fund and closed its office in Venice.

He supported Prism’s decision as being best for the business and said he could have stayed on — Prism is still deploying the rest of its fifth fund. But, he said, “the prospect of being a satellite in a home office with a partnership that needs to be face-to-face, serving its portfolio, was not a setup that I thought was great for either group.”

Also, “the (venture) industry is at a challenging precipice. My happiest professional days were as an operating person, I was told by my wife.”

Alnara Pharma Raises $20 Million

Alnara Pharmaceuticals Inc., a Boston-based developer of non-systemic protein therapeutics for the treatment of metabolic and inflammatory diseases, has raised $20 million in Series A funding. Frazier Healthcare Ventures and Third Rock Ventures co-led the deal, and were joined by Bessemer Venture Partners.

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget